Alnylam Pharmaceuticals Inc (ALNY)vsTheravance Biopharma Inc (TBPH)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
TBPH
Theravance Biopharma Inc
$15.29
+2.62%
HEALTHCARE · Cap: $726.14M
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 3356% more annual revenue ($3.71B vs $107.46M). TBPH leads profitability with a 98.5% profit margin vs 8.5%. TBPH trades at a lower P/E of 25.1x. TBPH earns a higher WallStSmart Score of 63/100 (C+).
ALNY
Hold49
out of 100
Grade: D+
TBPH
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Margin of Safety
-402.8%
Fair Value
$3.88
Current Price
$15.29
$11.41 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Every $100 of equity generates 45 in profit
Keeps 99 of every $100 in revenue as profit
Strong operational efficiency at 43.6%
Revenue surging 144.7% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
Moderate valuation
0.0% earnings growth
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : TBPH
The strongest argument for TBPH centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 98.5% and operating margin at 43.6%. Revenue growth of 144.7% demonstrates continued momentum.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : TBPH
The primary concerns for TBPH are P/E Ratio, EPS Growth, Market Cap.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while TBPH is a growth play — different risk/reward profiles.
ALNY carries more volatility with a beta of 0.38 — expect wider price swings.
TBPH is growing revenue faster at 144.7% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
TBPH scores higher overall (63/100 vs 49/100), backed by strong 98.5% margins and 144.7% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Theravance Biopharma Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe, and Asia. The company is headquartered in George Town, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?